

SCIENTIFIC PROGRAM

THURSDAY, OCTOBER 1, 2026		
07:30 - 08:15	Registration	
08:15 - 08:20	Welcome	
08:20 - 08:30	History of LVV/PMR Meeting	E. Matteson (Online)
08:30 - 10:00	Epidemiology and Classification of LVV	
08:30 - 08:50	New Insights Learned From The Epidemiology of LVV	Sara Monti
08:50 - 09:10	LVV-Spectrum Disease - GCA/PMR (GPSD)	Bhaskar Dasgupta
09:10 - 09:30	Classification of TAK Among LVV and IMIDs	Haner Direskeneli
09:30 - 09:45	Discussion	
09:45 - 10:15	COFFEE BREAK AND POSTER VIEWING	
10:15 - 12:00	Genetics and Pathophysiology of LVV	
10:15 - 10:45	Pathogenesis of LVV - GCA and TAK - Similarities and Differences	C. Weyand (Online)
10:45 - 11:05	Genetics of GCA	Ann Morgan
11:05 - 11:25	Functional Insights Into The Genetic Basis of TAK	Amr Sawalha
11:25 - 11:45	Pathogenesis of PMR - IL-6, IL-17 and Beyond	Elisabeth Brouwer
11:45 - 12:00	Discussion	
12:00 - 13:15	SATELLITE SYMPOSIUM - LUNCH BREAK	
13:15 - 14:15	Oral Abstract	
14:30 - 15:30	Workshops and Meet The Experts 1	
	Fast-Track GCA Clinic: How to Set-Up?	Cristina Ponte
	Biomarkers in LVV and PMR: Use in Clinical Practice	Maria Cid
	Long-Term Outcomes and Mortality in TAK	Durga Misra
	How to Approach Isolated and Silent Aortitis	K. Warrington (Online)
15:30 - 16:15	COFFEE BREAK AND SELECTED POSTER TOUR	
16:15 - 18:00	Imaging in The Diagnosis and Monitoring of LVV	
16:15 - 16:45	Debate 1: Which Imaging Technique to Diagnose and Follow-Up GCA? PET-CT vs Doppler US	Daniel Blockmans Wolfgang Schmidt
16:45 - 17:05	Ultrasound Scoring in LVV: Are We Ready for Routine Clinical Use?	Christina Duftner
17:05 - 17:25	AI and New Imaging Techniques in LVV	Valentin Schafer
17:25 - 17:45	Imaging in PMR	Milena Bond
17:45 - 18:00	Discussion	
18:00 - 18:30	Debate 2: Imaging in TAK - Treatment Decisions Should be Based on Imaging Results - In Favor or Not?	Alessandro Tomelleri Tanaz Kermani
FRIDAY, OCTOBER 2, 2026		

	Workshops and Meet The Experts in Breakfast 2	
07:30 - 08:30	Assessment of Disease Activity and Damage in TAK	Alexander de Souza
	Difficult-to-Treat GCA - How to Approach?	Aloja Hocevar
	Optimal Use of Glucocorticoids in LVV-PMR	Sebastian Unizony
	Mimics of LVV	Ömer Karadağ
	Pediatric TAK	Özgür Kasapçopur
08:30 - 09:30	Treatment of GCA PMR and TAK	
08:30 - 08:50	2026 EULAR Recommendations for The Management of LVV	Chetan Mukhtyar
08:50 - 09:10	Treat-to-Target in GCA and PMR	Christian Dejaco
09:10 - 09:30	Strategies for Tapering and Withdrawing Treatment for LVV and PMR	Peter Merkel
09:30 - 10:00	Debate 3: TAK Treatment TNF-Inhibitors Should be The First Line Biologic in Most Patients with TAK. Tocilizumab Should be The First Line Biologic in Most Patients with TAK. Discussion: Personalized Approach - Which Drug for Which Patient?	Fatma Alibaz David Saadoun
10:00 - 11:00	COFFEE BREAK AND SELECTED POSTER TOUR	
11:00 - 11:30	Debate 4: GCA Treatment Upadacitinib Should be The First Line GC-Sparing Agent in Most Patients with GCA. Tocilizumab Should Stay The First Line GC-Sparing Agent in Most Patients with GCA. Discussion: Personalized Approach - Which Drug for Which Patient?	Bernard Hellmich Sarah Mackie
11:30 - 12:30	Best Abstracts Presentation of Selected Abstracts and Best Abstracts Award	
12:30 - 13:30	SATELLITE SYMPOSIUM	
13:30 - 14:30	LUNCH BREAK AND POSTER VIEWING	
	Workshops and Meet The Experts 3	
14:30 - 15:30	Management Guidelines in LVV: Discussion	Takahiko Sugihara Carol Langford Carlo Salvarani
	What's New in Treatment of PMR?	Frank Buttgerit
	New Agents in TAK: JAKi and Beyond	Ruchika Goel
	Vascular Interventions in TAK	Emire Seyahi
15:30 - 16:00	COFFEE BREAK	
16:00 - 17:40	Other Diseases and Comorbidities Associated with LVV	
16:00 - 16:20	Management of Cardiovascular Risk Factors in LVV	Taryn Youngstein
16:20 - 16:40	Large-Vessel Involvement in Behçet's Disease	Gülen Hatemi
16:40 - 17:00	VEXAS Syndrome	Peter Grayson
17:00 - 17:20	LVV in Monogenic Syndromes	Ahmet Gül
17:20 - 17:40	What's Next for Research in GCA, TAK, and PMR?	Peter Merkel
17:40 - 18:00	Concluding Remarks and Farewell	